Dr. Dellinger is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1500 Duarte Rd
MOB 1002B
Duarte, CA 91010Phone+1 626-471-9353Fax+1 626-471-7155
Summary
- Thanh Dellinger, MD, is a specialist in Obstetrics & Gynecology, with a subspecialty in Gynecologic Oncology, located in Duarte, CA. She is an experienced practitioner in various areas like ovarian carcinoma, hyperthermic intraperitoneal chemotherapy, and robotic gynecologic surgery. Dr. Dellinger pursued her medical education at the University of California and subsequently completed her Residency and Fellowship at Penn State Milton S Hershey Medical Center and University of California respectively. Her career includes positions of increasing responsibility at the City of Hope Comprehensive Cancer Center, where she currently serves as an Associate Professor and Fellowship Program Director. Dr. Dellinger also has an impressive history of research with numerous publications related to gynecologic oncology and has conducted multiple clinical trials in areas related to ovarian, endometrial, and peritoneal cancer.
Education & Training
- University of California (Irvine)Fellowship, Gynecologic Oncology, 2008 - 2012
- Penn State Milton S Hershey Medical CenterResidency, Obstetrics and Gynecology, 2004 - 2008
- University of California, Irvine, School of MedicineClass of 2004
- University of California, San DiegoBS, Biochemistry , 1995 - 1999
Certifications & Licensure
- CA State Medical License 2008 - 2026
- PA State Medical License 2004 - 2008
- American Board of Obstetrics and Gynecology Obstetrics & Gynecology
- American Board of Obstetrics and Gynecology Gynecologic Oncology
Clinical Trials
- Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer Start of enrollment: 2014 May 19
- Megestrol Acetate With or Without Pterostilbene in Treating Patients With Endometrial Cancer Undergoing Hysterectomy Start of enrollment: 2019 Jan 21
- PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer Start of enrollment: 2020 Aug 21
Publications & Presentations
PubMed
- 11 citationsCharacterizing impact of positive lymph node number in endometrial cancer using machine-learning: A better prognostic indicator than FIGO staging?Colton Ladbury, Richard Li, Jay C. Shiao, Jason Liu, Mihaela C. Cristea
Gynecologic Oncology. 2021-11-15 - 18 citationsA phase I trial of intraperitoneal nab-paclitaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavityMihaela C. Cristea, Paul Frankel, Timothy W. Synold, Saul E. Rivkin, Dean Lim
Cancer Chemotherapy and Pharmacology. 2019-01-08 - 31 citationsIntraperitoneal Administration of Neural Stem Cell-Nanoparticle Conjugates Targets Chemotherapy to Ovarian Tumors.Pengpeng Cao, Rachael Mooney, Revathiswari Tirughana, Wafa Abidi, Soraya Aramburo
Bioconjugate Chemistry. 2017-05-18
Journal Articles
- A Collaborative Surgical Approach to Upper and Lower Abdominal Cytoreductive Surgery in Ovarian CancerByrne Lee, Mark T Wakabayashi, Ernest S Han, Thanh H Dellinger, Andrew M Blakely, Bertram Yuh, Journal of Surgical Oncology
Press Mentions
- How Data for ImmunoGen Drug Could the Way Doctors Treat Ovarian CancerJune 6th, 2023
Professional Memberships
- Member
Other Languages
- German
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: